Trial
NCT05032066
A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Amgen
Collaborators
—
Condition
Idiopathic Pulmonary Fibrosis
Intervention
HZN-825
Why stopped
The trial was terminated due to not meeting primary or key secondary endpoints.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-03